: CVRx started at buy with $30 stock price target at Canaccord Genuity

1 BUSINESS

Business News - Opportunities - Reviews

 

 

CVRx Inc.

CVRx, Inc. develops proprietary active implantable technology to treat high blood pressure and heart failure. It has developed the second generation Barostim neo, an implantable system designed to treat heart failure and hypertension. It operates through the following geographical segments: United States, Germany, and Other Countries. The company was founded by Robert S. Kieval and Tyler P. Lipschultz in August 2000 and is headquartered in Minneapolis, MN.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply